The Super Shred blend is a compounded fat loss peptide stack combining three peptides with complementary mechanisms for body recomposition: AOD-9604 (the lipolytic fragment of human growth hormone), CJC-1295 (a GHRH analog), and Ipamorelin (a selective GH secretagogue). The protocol is designed to promote fat oxidation through both direct lipolytic action (AOD-9604) and enhanced endogenous growth hormone secretion (CJC-1295 + Ipamorelin), while preserving lean body mass.

Overview

The Super Shred blend addresses fat loss through two complementary strategies: direct activation of fat-burning pathways independent of GH receptor signaling (AOD-9604), and enhancement of endogenous GH secretion to promote lipolysis, improve body composition, and maintain lean mass (CJC-1295 + Ipamorelin).

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that retains the lipolytic activity of GH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from GH receptor activation. CJC-1295 and Ipamorelin work synergistically to amplify endogenous GH pulses through dual GHRH/GHS receptor activation, providing the anabolic and metabolic benefits of elevated GH without exogenous GH administration.

The combination is used in clinical and compounding pharmacy settings as an adjunct to caloric deficit and exercise programs for individuals seeking enhanced fat loss with lean mass preservation. No clinical trials have evaluated this specific three-peptide combination.

Mechanism of Action

Direct Lipolysis (AOD-9604)

• Beta-3 adrenergic receptor pathway: AOD-9604 stimulates lipolysis in adipose tissue through a mechanism involving beta-3 adrenergic receptor signaling, independent of the GH receptor. This direct fat-burning pathway does not require GH receptor activation and does not produce the insulin resistance associated with full-length GH (Heffernan et al., 2001)
• Lipogenesis inhibition: AOD-9604 also inhibits de novo lipogenesis (new fat synthesis), providing a dual mechanism of reducing fat stores by both increasing fat breakdown and decreasing fat formation
• No diabetogenic effect: Unlike full-length GH, AOD-9604 does not increase fasting glucose or insulin resistance, making it suitable for individuals where metabolic safety is a concern

GH-Mediated Lipolysis (CJC-1295 + Ipamorelin)

• CJC-1295 (GHRH pathway): Activates GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion. GH directly activates hormone-sensitive lipase in adipocytes, promoting triglyceride hydrolysis
• Ipamorelin (GHS-R1a pathway): Amplifies GH pulses through ghrelin receptor activation and somatostatin suppression. Highly selective for GH -- does not increase cortisol (which promotes visceral fat deposition) or prolactin
• IGF-1 elevation: The CJC-1295/Ipamorelin combination elevates IGF-1, which promotes protein synthesis and lean mass preservation during caloric deficit -- critical for body recomposition rather than simple weight loss

Reconstitution Calculator

Research

Safety Profile

Safety is based on individual component data, as no studies have evaluated the three-peptide combination:

• AOD-9604: Well-tolerated in clinical trials. No significant adverse events beyond injection site reactions. No effect on glucose metabolism, insulin sensitivity, or IGF-1 levels (key safety advantage).
• CJC-1295: Transient flushing, headache, dizziness at injection. Theoretical concerns about sustained IGF-1 elevation with long-term use.
• Ipamorelin: Generally well-tolerated. Minimal cortisol and prolactin effects (advantage over GHRP-2/GHRP-6). Transient headache, flushing.
• Combined: No drug interaction or combined safety data available. Additive GH-stimulatory effects could theoretically produce excessive GH/IGF-1 elevation if combined with other GH-boosting agents.

Pharmacokinetic Profile